Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $72.00 USD
Change Today +1.53 / 2.17%
Volume 429.5K
AMAG On Other Exchanges
Symbol
Exchange
Berlin
As of 8:10 PM 07/6/15 All times are local (Market data is delayed by at least 15 minutes).

amag pharmaceuticals inc (AMAG) Snapshot

Open
$70.15
Previous Close
$70.47
Day High
$72.64
Day Low
$70.01
52 Week High
06/24/15 - $74.21
52 Week Low
07/18/14 - $17.79
Market Cap
2.2B
Average Volume 10 Days
702.1K
EPS TTM
$5.27
Shares Outstanding
30.5M
EX-Date
--
P/E TM
13.7x
Dividend
--
Dividend Yield
--
Current Stock Chart for AMAG PHARMACEUTICALS INC (AMAG)

Related News

No related news articles were found.

amag pharmaceuticals inc (AMAG) Related Businessweek News

No Related Businessweek News Found

amag pharmaceuticals inc (AMAG) Details

AMAG Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that focuses on maternal health, anemia, and cancer supportive care. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women with a singleton pregnancy; Feraheme (ferumoxytol) injection for use as an intravenous (IV) iron replacement therapy for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. The company markets Feraheme in the United States and Canada; and as Rienso in the European Union. It sells Feraheme to authorized wholesalers and specialty distributors. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.

257 Employees
Last Reported Date: 02/18/15
Founded in 1981

amag pharmaceuticals inc (AMAG) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $534.6K
President and Chief Operating Officer
Total Annual Compensation: $435.8K
Chief Accounting Officer, Senior Vice Preside...
Total Annual Compensation: $277.9K
Compensation as of Fiscal Year 2014.

amag pharmaceuticals inc (AMAG) Key Developments

AMAG Pharmaceuticals, Inc., CBR Systems, Inc. - M&A Call

To discuss definitive agreement to acquire Cord Blood Registry

AMAG Pharmaceuticals Appoints Aaron Pelta as Vice President of Business Development

AMAG Pharmaceuticals, Inc. announced the appointment of Aaron Pelta as vice president of business development and transactions, reporting to Melissa Klug, senior vice president of business development and strategy. Mr. Pelta comes to AMAG with more than 15 years of experience in corporate and business development, commercialization, strategy and operations, having executed multiple mergers, acquisitions and licensing deals. Prior to joining AMAG, Mr. Pelta served in various positions of increasing responsibility in the business development and commercial groups at Cubist Pharmaceuticals from 2004 to 2015, including senior director, business development, where he led the transaction teams responsible for the acquisitions of Optimer Pharmaceuticals and Adolor Pharmaceuticals.

AMAG Pharmaceuticals, Inc. Partners with NurseWise to Launch New Patient Compliance Program

AMAG Pharmaceuticals, Inc. has announced that its Lumara Health division has partnered with NurseWise to launch My Adherence Program, a new program designed to facilitate enhanced patient compliance with Makena therapy. Makena is the only FDA-approved treatment indicated to reduce the risk of preterm birth in women who are pregnant with one baby and who have delivered one preterm baby spontaneously in the past. Makena is a weekly injection administered by a healthcare provider, starting as early as week 16 of the pregnancy, and given weekly until week 37 or the baby is born, whichever occurs first. Each expecting mother who has been prescribed Makena and enrolls (at no additional cost) in My Adherence Program will be paired with a dedicated maternal health nursing specialist who will contact the patient weekly to: educate patients on the importance of achieving a full-term pregnancy; provide educational materials that address important topics during pregnancy, such as coping with stress, good nutrition, relaxation techniques, and when applicable, recommendations for stopping smoking and drug use during pregnancy; encourage adherence to the weekly Makena injection schedule; identify barriers to adherence and provide potential solutions to overcome those barriers; and empower patients to take an active role in their health.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AMAG:US $72.00 USD +1.53

AMAG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AMAG.
View Industry Companies
 

Industry Analysis

AMAG

Industry Average

Valuation AMAG Industry Range
Price/Earnings 13.3x
Price/Sales 9.9x
Price/Book 3.2x
Price/Cash Flow 13.8x
TEV/Sales 6.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMAG PHARMACEUTICALS INC, please visit www.amagpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.